Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

Einav Ratzon1, Yousef Najajreh2, Rami Salem2, Hazem Khamaisie1, Martin Ruthardt3 and Jamal Mahajna1,4*

Abstract
Background: Platinum-based drugs are used as cancer chemotherapeutics for the last 40 years. However, drug resistance and nephrotoxicity are the major limitations of the use of platinum-based compounds in cancer therapy. Platinum (IV) complexes are believed to act as platinum prodrugs and are able to overcome some of platinum (II) limitations.

Methods: A number of previously sensitized platinum (IV) complexes were evaluated for their anti-cancer activity by monitoring ability to affect proliferation, clonigenicity and apoptosis induction of Cisplatin sensitive and resistant cancer cells. In addition, the uptake of Cisplatin and the platinum (IV) derivatives to Cisplatin sensitive and resistant cancer cells was monitored.

Results: The bis-octanoatoplatinum (IV) complex (RJY13), a Cisplatin derivative with octanoate as axial ligand, exhibited strong anti-proliferative effect on the Cisplatin resistant and sensitive ovarian cells, A2780cisR and A2780, respectively. Moreover, RJY13 exhibited good activity in inhibiting clonigenicity of both cells. Anti-proliferative activity of RJY13 was mediated by induction of apoptosis. Interestingly, a bis-lauratoplatinum (IV) complex (RJY6) was highly potent in inhibiting clonogenicity of both Cisplatin sensitive and Cisplatin resistant cells, however, exhibited reduced activity in assays that utilize cells growing in two dimensional (2D) conditions. The uptake of Cisplatin was reduced by 30% in A2780 in which the copper transporter-1 (Ctr1) was silenced. Moreover, uptake of RJY6 was marginally dependent on Ctr1, while uptake of RJY13 was Ctr1-independent.

Conclusions: Our data demonstrated the potential of platinum (IV) prodrugs in overcoming acquired and inherited drug resistance in cancer cell lines. Moreover, our data demonstrated that the uptake of Cisplatin is partially dependent on Ctr1 transporter, while uptake of RJY6 is marginally dependent on Ctr1 and RJY13 is Ctr1-independent. In addition, our data illustrated the therapeutic potential of platinum (IV) prodrugs in cancer therapy.

Keywords: Platinum (IV), Cisplatin, Ovarian cancer, Resistance, Copper transporter (Ctr1)

Background
cis-Diaminedichloroplatinum (II) [cis-[PtCl2(NH3)2], CDDP, Cisplatin] known for decades as Peyrone’s salt, was first synthesized by M. Peyrone in 1845. Its cytotoxic activity was reported in 1964 by Rosenberg [1], and its anti-cancer activity in 1979. Cisplatin is routinely employed for the treatment of testicular and ovarian cancers and is being increasingly used against cervical, bladder, and head/neck tumors. The mechanism of action of Cisplatin is based on the intrastrand cross-linking of the cis-Pt(NH3)2 unit to cellular DNA at two neighboring guanine bases [2] and the consequent induction of cellular apoptosis. Nevertheless, its full clinical utility is limited due to some adverse side effects.

Primary and acquired drug resistance is a major limitation of the platinum compounds use as an anti-cancer therapy [3, 4]. The molecular mechanisms that underline this chemo resistance are largely unknown. Possible mechanisms include decreased platinum accumulation, elevated
drug inactivation by metallothioneine and glutathione, and enhanced DNA repair activity [2, 5]. Moreover, acquired and inherited resistance of cancer cells were reported to be also mediated by altered molecular mechanisms and activated signaling pathways, such as the protein kinase B/mammalian target of rapamycin (Akt/mTOR) which is also implicated in Cisplatin resistance in human ovarian cancer cells [6].

In an attempt to overcome the above mentioned short-ages, two platinum compounds were introduced to the clinic; Carboplatin and Oxaliplatin [7, 8]. Carboplatin, though much less potent than Cisplatin, have shown fewer adverse effects. Nonetheless, the drug showed cross-resistance with Cisplatin, while Oxaliplatin did not [9, 10]. Moreover, a third generation orally available lipophilic platinum, Satraplatin, demonstrated promising antitumor activity in multiple settings with a better toxicity profile than Cisplatin [11, 12]. However, it has recently been abandoned in phase III clinical trials for the treatment of hormone-refractory prostate cancer [13]. It is well-established that platinum (II) adverse effects are caused mainly by its ability to non-selectively bind to macromolecules, leading to reduced bioavailability and increased toxic side effects. Platinum (IV) complexes, on the other hand, have enormous potential as anticancer agents in terms of both high activity and low toxicity. These potential advantages of Platinum (IV) complexes, which expected to remain in higher oxidation state in the bloodstream, are derived from their lower reactivity towards macromolecules, which enables to diminish the loss of active drug and lower the incidence of unwanted side reactions that lead to toxic side effects. The octahedral platinum (IV) geometry makes these compounds far more kinetically inert towards ligand exchange reactions and less prone to substitution reactions in the physiological media, thus making such compounds of high interest in avoiding the adverse toxic effects seen with platinum (II). In addition, once entered the cell, platinum (IV) is bio- converted to the corresponding platinum (II) species by expelling the axial ligands (Fig. 1). Together, the above mentioned observations laid down the bases for the rational that Platinum (IV) compounds have the potential of acting as prodrugs for their counter platinum (II) active forms (Fig. 1) [14]. However, the first such chemotherapeutic agent, namely satraplatin, failed to receive approval. Moreover, others also questioned the above prodrug rational and pointed toward the ability of paltinum (IV) prodrug to be reduced extracellularly [15, 16].

Recently, a series of complexes of the general formula cis, cis, trans-[diaminedichloro-bis-carboxylato-PLAT(IV)], where the carboxylate ranges between heptanoate, octanoate, decanoate, laurate, myristate, palmitate, stearate, and olateandelaidate, were prepared (Fig. 1), characterized, and their anti-proliferative and anti-clonigenicity properties against cancer cells were evaluated. Our results showed that complexes encompassing saturated fatty acid derivatives were generally more potent than the unsaturated ones.

Two promising platinum (IV) prodrugs, RJY6 and RJY13 were selected for the evaluation of their anti-cancer activity against several cancer cell lines including ovarian and colon cancer cells. Here, we report that while RJY13 was highly potent in inhibiting proliferation and clonogenicity of both Cisplatin sensitive and Cisplatin resistant cancer cells, RJY6 was highly active in the clonogenicity assay but exhibited reduced activity in assays that utilize cells growing in 2D condition (plastic). Moreover, uptake of the two platinum (IV) prodrugs was largely Ctrl-independent which accounts, in part, for the enhanced activity against Cisplatin resistant cancer cells.

Methods

Materials

Cisplatin, Carboplatin and Oxaliplatin were purchased from Sigma. Stock solutions were 25–50 mM in phosphate-buffered saline (PBS) and diluted were made with PBS to reach the appropriate concentrations in the different assays. RJYs were synthesized at the laboratory of Anticancer Drugs Research Lab, Faculty of Pharmacy, Al-Quds University, Jerusalem, Abu-Dies, Palestine and dissolve in dimethyl sulfoxide (DMSO) (25-50 mM) and diluted to obtain final DMSO solutions of 0.1–0.5 % in the different assays.

Synthesized Platinum (IV) prodrugs were subjected to proton nuclear magnetic resonance (1H-NMR) and 195Pt-NMR spectroscopy using Varian Unity Inova 500 MHz spectrometer equipped with a 5-mm switchable and data were processed using the VNMR software. Moreover, infrared spectra were obtained from a KBr matrix (4000–400 cm-1) using a PerkinElmer Precisely, Spectrum 100, fourier transform infrared spectroscopy (FT-IR) spectrometer. Furthermore, to all synthesized prodrugs an Electrospray ionization mass spectrometry (ESIMS) was performed using a ThermoQuest Finnigan LCQ-Duo in the positive ion mode (Najajreh et al., in preperation).

Obtained data for the compound RJY6 (Cis, cis, trans-[diaminedichloro-bis-lauratoplatinum(IV)]) were as follow: yellowish solid product with yield of 35 %, 195Pt-NMR: (DMSO-d6, δ ppm) = 1204.25 and FT-IR (KBr) (cm-1): 3403(N-H), 1560 (C = O), 540(Pt-O). Obtained data for the compound RJY13 (Cis, cis, trans-[diaminedichloro-bis-octanoatoplatinum (IV)]): were as follow: yellowish solid product with of 28 %, 195Pt-NMR: (DMSO-d6, δ ppm) = 1203.40 and FT-IR (KBr) (cm-1): 3125 (N-H), 1580 (C = O), 527 (Pt-O).

Cells and cancer cell lines

Colon cancer (HT29), prostate cancer (PC3), Cisplatin sensitive ovarian cancer (2780), and Cisplatin resistant
ovarian cancer cell lines (A780cisR) were obtained from ATCC (ATCC, USA). Cells were grown in Roswell Park Memorial Institute (RPMI) 1640 (Sigma, Rehovot, Israel) containing 2 mM L-glutamine, 10 % fetal bovine serum (FBS), 100 IU/ml penicillin, and 100 μg/ml streptomycin (PenStrep). The human embryonic kidney cell line 293A (HEK293A), human embryonic kidney cell line 293 T (HEK293T) and human foreskin fibroblast cells (HFF) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) medium (Sigma, Rehovot, Israel) supplemented with 10 % fetal calf serum (FCS), 2 mM L-glutamine, 1 mM sodium pyruvate, and 1 % PenStrep (Biological Industries, Israel). All cell lines were grown at 37 °C in a humidified atmosphere with 5 % CO₂.

Cell proliferation assay
(2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium -5-carboxanilide) (XTT) assay was used as previously described [17] to evaluate the cytotoxicity of the different Cisplatin derivatives. Briefly, cells (1.5 × 10⁴) were plated in RPMI 1640 medium using 96-well plates for 24 h, and then treated for an additional 72 h with the different Cisplatin derivatives. A total of 50 μl of XTT solution were added to each well and incubated for 3 h at 37 °C. The optical density was measured by a multi-well plate spectrophotometer at 450 nanometers with a references’ wavelength of 630 nm. The concentrations inhibiting cell proliferation by 50 % (IC₅₀) of all tested derivatives were calculated. The experiment was performed in triplicate, and standard deviations were also calculated.

Apoptosis assay
To monitor apoptosis potential of Cisplatin derivatives we followed cleavage of poly ADP ribose polymerase (PARP) protein [18]. Briefly, cells (2 × 10⁵ cells/ml) were treated with Cisplatin derivatives for the indicated time. Cells were collected, washed once with cold PBS, and lysed in buffer [10 mMTris-HCl (pH 7.4), 100 mMNaCl, 100 mMEDTA, 20 mM MgCl2] and 1% Triton X-100. The samples were incubated at 4°C for 1 h. The supernatant was collected and the protein concentration was measured using the Bradford method. The PARP assay was performed using the In Vitro Cell Death Detection ELISA Plus kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. The absorbance was measured at 450 nm, and the results were compared with a standard curve of known concentrations of PARP. The experiment was performed in triplicate, and standard deviations were also calculated.

Fig. 1 Chemical structure of Cisplatin (IV) prodrugs and cellular bio-reduction. a. Bio-reduction of Cisplatin (IV) prodrugs to give rise to the biologically active Cisplatin moiety and the different fatty acid ligands (R). b. Chemical structure of the two Cisplatin (IV) prodrugs: RJY6 and RJY13
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na3P2O7, 2 mM Na3VO4, 1 % Triton x-100, 10 % Glycerol, 0.1 % sodium dodecyl sulfate (SDS), 0.5 % deoxycholate, 1 mM phenylmethylsulfone fluoride (PMSF), for 30 min at 4 °C. Cell lystate supernatants (40 μg protein/each) were resolved on 8 % SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and analyzed by immune-blotting with an anti-cleaved PARP antibody (Cell signaling technology, USA ). Anti α-tubulin antibody (Santa Cruz Co., CA, USA) was used as a loading control.

PathScan cleaved PARP (Asp214) sandwich enzyme-linked immunosorbent assay (ELISA)
Cell lysates prepared from treated ovarian cancer cells (30 h) were used for quantitative measurement of cleaved PARP according to manufacturer’s instructions (Cell signaling technology, USA). In our experiments, 20 μg of total lystate proteins from each sample were utilized.

Clonigenicity assay
Clonigenicity assay was performed as previously describe [19]. Briefly, cells (1 × 10⁵) in 1 ml RPMI 10 % FBS medium were diluted in 1 ml of 0.6 % agar to give a final agar concentration of 0.3 % agar. The cells-agar mixture was poured over a hardened agar base in wells of 12-well plates and allowed to solidify. Once the top layer solidified, 1 ml of medium containing different treatments was placed on top to keep the agar moist. The cells were grown at 37 °C in a 5 % CO₂ humidified atmosphere until colonies were visible (2 weeks). The plates were stained for 4 h with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide (MTT), and the dye was extracted with 1 ml solubilization buffer (20 % SDS, 50 % N,N-dimethyl-formamide, 25 mM HCL) for 24 h. The optical density was measured at 570 nm wavelength with a reference wavelength of 630 nm.

Inductively coupled plasma mass spectrometry (ICP-MS)
To monitor the uptake potential of Cisplatin and Cisplatin (IV) prodrugs into A2780, A2780cisR, and A2780 Ctrl1 - cell lines, experiment was carried out as previously described [20]. Briefly, cells were plated at 5×10⁵ cells/ml, and on the following day compounds RJY6, RJY13 (10 microM), and Cisplatin (50 microM) were added for 1 h. Cells were collected, washed four times with cold PBS. The cells were counted, digested, and the amount of platinum in the cells was determined by ICP-MS. The amount of platinum/cell was calculated.

Silencing of Ctr1 in A2780 cells
A2780 cells were transfected with three different shRNA Ctr1 constructs (Sigma-Aldrich, Rehovot, Israel) according to manufacturer instructions. Briefly, Ctr1 shRNA plasmid DNA, pcMV-dR8.2 dvpr and pcMV-VSVG were co-transfected into HEK293T cells (1.5×10⁶ cells/ml) using Fugene 6 (Roche Applied Science, Penzberg, Germany) according to manufacturer instructions. The supernatant of the infected cells was collected 48 h post transfection and used to infect A2780 cells, after which Puromycin resistant clones were selected. Levels of Ctr1 were determined in parental and Puromycin resistant A2780 clones to calculate percentage of silencing.

Statistical analysis
Statistical analysis was performed using Student’s t-test, with significant values set at *P < 0.05 or **P < 0.005.

Results
Evaluation the anti-proliferative effects of Cisplatin (IV) prodrugs on ovarian cancer cell lines
Previously, a number of Cisplatin (IV) prodrugs carrying fatty acid ligands were synthesized (Najaireh et al., in preparation). In this report, we evaluated the activity of Cisplatin (IV)-Fatty acid conjugates against A2780 and A2780cisR, ovarian cancer cells that are sensitive and resistant to Cisplatin, respectively (Fig. 1). The anti-proliferative effect of Cisplatin (IV) fatty acid conjugates, in comparison to Cisplatin and Oxaliplatin, are summarized in Table 1.

Data presented in Table 1 illustrated that the two ovarian cancer cell lines showed varying sensitivity to Cisplatin, with IC₅₀ of 1.3 and 19.2 microM against A2780 and A2780cisR, respectively. Similarly, Cisplatin (IV) fatty acid conjugates exhibited variable potency against the two ovarian cancer cell lines (Table 1). The IC₅₀ values of the two active derivatives, RJY6 and RJY13, were 0.7 and 0.08 microM, respectively, against the sensitive ovarian cancer cells and 3.3 and 0.57 microM, respectively, against the A2780cisR resistant ovarian cancer cells. Thus, RJY13 exhibited increased potency, ranged from 16 to 33 fold against A2780 and A2780cisR, respectively. However, RJY6 exhibited a moderate increase in potency of about 5-6 fold against the two ovarian cancer cell lines. Similarly, the platinum (IV) prodrugs also exhibited enhanced activity against K562; chronic myelogenous leukemia (CML) cell lines (Table 1) and the two active platinum (IV) prodrugs, RJY6 and RJY13 exhibited enhanced anti-CML by 4 and 7 folds, respectively, compared to Cisplatin.

Clonogenicity inhibition by Cisplatin (IV) prodrugs
Anchorage-independent growth of cells (three dimensional, 3D growth) is a typical characteristic of the tumorigenicity of cancer cells in vitro [21]. Thus, the anti-clonogenicity potential of the Cisplatin (IV) prodrugs was evaluated (Fig. 2). Figure 2 shows a photograph of a representative experiment conducted with A2780, A2780cisR, and HT29 cell lines. Clonogenicity inhibition was observed in Cisplatin treated samples with IC₅₀ of 2300 and 4200 nM when
A2780 and A2780cisR, respectively, were used. Furthermore, Oxaliplatin exhibited enhanced potency toward the two cell lines compared to Cisplatin, with IC\textsubscript{50} of 180 and 1600 nM against A2780 and A2780cisR, respectively. Interestingly, our platinum (IV) prodrugs exhibited enhanced activity against both cell lines. Our data showed that RJY1, RJY3, RJY4, RJY6, RJY13, RJY18 and RJY19 exhibited good potency against A2780 cells with IC\textsubscript{50} of 180, 70, 25, 15, 10, 150, and 120 nM, respectively, an increased potency by 10–200 fold among the different derivatives and in comparison to Cisplatin (Fig. 2e). Moreover, a number of derivatives were also effective against the Cisplatin resistant, A2780cisR, cell line, with comparable activity to that observed against the sensitive cell lines, A2780. Of special interest is the derivatives RJY1, RJY2, RJY6, RJY13, RJY18, and RJY19 that effectively inhibited clonogenicity of the Cisplatin resistant ovarian cell line with IC\textsubscript{50} of 320, 210, 13, 10, 150, and 220 nM, respectively. The two derivatives, RJY13 and RJY6, were significantly more potent than Cisplatin or Oxaliplatin in inhibiting the clonogenicity of the ovarian cancer cell lines tested (Fig. 2) with IC\textsubscript{50} values lower by more than 20–30 folds than Cisplatin. Moreover, the Cisplatin (IV) prodrugs, and especially RJY13 and RJY6, exhibited significant activity against the inherently resistant cells such as HT29 and PC3 cell lines (Fig. 2).

Next, we selected RJY6 and RJY13 to evaluate their ability to affect proliferation of non-cancerous cells using the HFF, HEK293A and HEK293T cells. HEK293A is an engineered HEK293 cells carrying human species C adenovirus serotype 5 (Ad5) DNA, while HEK293T is carrying the simian vacuolating virus 40 (SV40) large T-antigen. Cisplatin and other platinum (II) compounds exhibited a moderate degree of selectivity toward cancer cells compared to normal cells, mainly due to altered DNA repair mechanism and status of p53 gene. In agreement with published data, we observed that Cisplatin exhibited some degree of selectivity toward A2780 ovarian cancer cell lines compared to HFF, HEK293A and HEK293T (Table 2). Similarly, carboplatin exhibited some degree of selectivity toward the ovarian cancer cells compared to HEK293 cells. Our two platinum (IV) prodrugs also exhibited selectivity toward ovarian cancer cells. RJY13 was more potent against A2780 compared to HEK293A/T by about 10 fold. Interestingly, RJY6 exhibited better selectivity profile of 16 and 24 fold when comparing potency against A2780 to HEK293T and HEK293A, respectively. Moreover, Cisplatin also exhibited good selectivity when comparing potency between A2780 to HFF cells. However, selectivity of RJY13 and RJY6 was reduced by 30 fold and enhanced by 117 fold, respectively, arguing that RJY6 compound is expected to exhibit reduced toxicity to normal tissues and will exhibit an improved therapeutic window. Interestingly, Cisplatin, Carboplatin and RJY6, but not RJY13 exhibited potent activity against HEK293T compared to HEK293A; probably due to compromise DNA repair in HEK293T resulted from impaired function of p53 in those cells.

### Induction of apoptosis by Cisplatin (IV) prodrugs in cancer cell lines

To investigate whether the effect of the RJY prodrugs is due to apoptosis induction or cell growth suppression, we monitored the ability of the Cisplatin (IV) prodrugs to promote PARP cleavage as a marker of apoptosis induction [18]. Ovarian cancer cells, A2780 and A2780cisR, were treated for 30 h (Fig. 3) with different concentrations of Cisplatin (IV) fatty acid conjugates and results were compared to the effect obtained with Cisplatin. Results shown in Fig. 3 illustrated that treatment with Cisplatin caused very minimal cleavage of PARP in A2780cisR at concentrations below 100 microM (Fig. 3b), while significant PARP cleavage was observed in A2780 cells exposed to 25 microM (Fig. 3a). Interestingly, 5 microM of RJY13 was sufficient to cause a significant PARP cleavage in A2780cisR and A2780 cells (Fig. 3a and b), arguing that RJY13 exhibited enhanced potency against the resistant as well as the sensitive ovarian cancer cells. In contrast, exposure to RJY6 caused PARP cleavage in both A2780cisR and A2780 cells using concentrations above 25 microM, demonstrating enhanced potency to the resistant ovarian cancer cell line in comparison to Cisplatin (Fig. 3a and b). Focusing on Cisplatin resistant ovarian cancer cells (A2780cisR), we

### Table 1 Anti-proliferative activity of Cisplatin (IV) prodrugs.

Anti-proliferative activity was determined according to Materials and Methods. IC\textsubscript{50} values of the different derivatives are in microM. Data shown are of representative experiment with CV below 15 % in all samples. Experiment was repeated three times with comparable outcome.

| Compound  | A2780 | A2780cisR | IC50 (μM) |
|-----------|-------|-----------|-----------|
| Cisplatin | 1.3   | 192       | 5.2       |
| Oxaliplatin | 12.7 | 15.5      | 3.2       |
| Carboplatin | 16.8 | 109       | ND        |
| RJY1      | >20   | >20       | 34        |
| RJY2      | 15.3  | 6         | 3.8       |
| RJY3      | >20   | 15        | 9.4       |
| RJY4      | 20    | 7         | 3.9       |
| RJY5      | >20   | >20       | >20       |
| RJY6      | 0.7   | 3.3       | 1.3       |
| RJY9      | >20   | >20       | >20       |
| RJY10     | 19.2  | >20       | >20       |
| RJY11     | >20   | >20       | >20       |
| RJY13     | 0.08  | 0.57      | 0.7       |
| RJY18     | 14    | 2.1       | 0.85      |
| RJY19     | 12.7  | 10        | 9.3       |
Fig. 2 Clonogenicity inhibition of Cisplatin (IV) prodrugs. Cancer cells A2780 (a, b), A2780cisR (a, c) and HT29 (a, d) were grown on soft agar and treated with 5, 0.5 and 0.05 microM of Cisplatin, Oxaliplatin, RJY6, RJY9, RJY11 and RJY13 or solvent-treated cells (a) according to Materials and Methods. IC_{50} values of clonogenicity inhibition of the different derivatives are in nM. Data shown are of representative experiment with coefficient of variation (CV) below 15% in all samples. Experiment was repeated three times with comparable outcome.
performed quantitative measurement of cleaved PARP using Pathscan cleaved PARP (Asp214) sandwich ELISA assay (Cell signaling, USA). Results shown in Fig. 3c demonstrated that Cisplatin was not active in inducing PARP cleavage in A2780cisR cells and only at the highest concentrations used, 25 microM, a 2.4 fold increase in the amount of cleaved PARP was observed (Fig. 3c). In contrast, a significant level of cleaved PARP was observed when A2780cisR were exposed to RJY13. Levels of cleaved PARP were increased by 4, 34 and 37 fold when cells were exposed to 1, 5 and 25 microM of RJY13, respectively (Fig. 3c) compared to untreated sample. Moreover, levels of cleaved PARP were also increased in cells treated with RJY6, but to a lesser extent compared to RJY13 (Fig. 3c). Levels of cleaved PARP were increased by 2, 3 and 21 fold when cells were exposed to 1, 5 and 25 microM of RJY6, respectively (Fig. 3c).

Involvement of Ctr1 in the uptake of Cisplatin and platinum (IV) prodrugs
Enhanced expression of hCtr1 was associated with increased accumulation of Cisplatin, arguing for a role of Ctr1 in mediating Cisplatin uptake [22]. Thus, we monitored the expression level of Ctr1 in A2780 and A2780cisR cells. Data presented in Fig. 4a illustrated that Ctr1 is expressed at very low levels in A2780cisR cells in comparison to the Cisplatin sensitive A2780 cell line. This argues that reduced Ctr1 expression might contribute to the reduced sensitivity to Cisplatin observed in A2780cisR cells. To further evaluate the role of Ctr1 in Cisplatin resistance, we infected A2780 cells with three shRNA targeting the human Ctr1 gene. Data presented in Fig. 4b demonstrated that the expression of Ctr1 in the resulted clones, #352,

Table 2 Selectivity Index of Cisplatin and active Cisplatin (IV) prodrugs. The IC50 of Cisplatin, RJY6 and RJY13 were determined using A2780, HFF, HEK293T and HEK293A cells. Data shown are of representative of three experiments with CV below 20 % in all samples

| Compound   | A2780 | HFF  | HEK293T | HEK293A |
|------------|-------|------|---------|---------|
| Cisplatin  | 1.3   | 84   | 3.2     | 16.3    |
| Carboplatin| 16.8  | ND   | 45      | 105     |
| RJY6       | 0.7   | 82   | 11.8    | 17.3    |
| RJY13      | 0.08  | 2.4  | 0.5     | 0.7     |

Fig. 3 PARP cleavage induced by Cisplatin (IV) prodrugs. A2780cisR (a, c) and A2780 (b) cells were treated with Cisplatin, RJY6 and RJY13 for 30 h as described in Materials and Methods. Quantitative evaluation of cleaved PARP in A2780cisR cells exposed to Cisplatin, RJY6 and RJY13 at (1, 5 and 25 microM) (c) were performed as described in Materials and Methods. P values: * P < 0.05 and **P < 0.005
#349, and #348, were silenced by 60, 5 and 90 %, respectively (Fig. 4b). Next, we evaluated the consequence of reduced expression of Ctr1 on Cisplatin uptake using ICP-MS. Figure 4c showed that uptake of Cisplatin into A2780 was significantly higher in comparison to A2780cisR. Moreover, silencing of Ctr1 in clone #348 caused a significant reduction (30 %) in Cisplatin uptake, but still higher than that of A2780cisR, arguing for the possibility that other transporters, alongside Ctr1, contribute to Cisplatin uptake in A2780 cell lines [23]. Next, we evaluated the uptake of RJY6 and RJY13 into the different A2780 cells. Figure 4d showed that uptake of RJY13 and RJY6 was efficient in all tested cells. Moreover, uptake of RJY13 and RJY6 was significantly higher than that of Cisplatin. For example, A2780 cells accumulated 0.00014 platinum /cells when they were exposed to 50 microM Cisplatin for 1 h. The same cells accumulated 0.0054 and 0.0041 platinum/cells when RJY6 and RJY13 were used, respectively, an increase of 30 fold in the uptake of the derivatives, which might explain, in part, the enhanced potency of RJY6 and RJY13 compared to the parental drug, Cisplatin. Furthermore, uptake of RJY11, a relatively non-active platinum (IV) derivative, was close to background in all A2780 cells, arguing that the activity of the different derivatives correlates with their cellular uptake (data not shown). Interestingly, uptake of RJY6 was significantly lower in A2780 cells with silenced Ctr1 (clone #348), and that in contrast to uptake of RJY13 that was not dependent on the presence of Ctr1 protein (Fig. 4d).

Discussion

Previously, we evaluated the activity of a number of platinum (IV) prodrugs for their anti-proliferative and clonogenicity inhibition of the CML cell lines (Najajreh et al., in preparation). In this study we focused on different parameters of our platinum (IV) series and evaluated anti-cancer activity targeting the A2780 and A2780cisR, Cisplatin sensitive and resistant ovarian cancer cell lines, respectively, including anti-proliferative, clonogenicity inhibition, apoptosis induction and drug uptake. In addition, we monitored the ability of our novel compounds to exert anti-proliferative and clonogenicity inhibition against inherently Cisplatin resistant cell lines such as HT29 and PC3 cells. In agreement with our previous data, two platinum (IV) prodrugs, RJY6 and RJY13, exhibited potent activity against ovarian cancer cells with comparable potency. In contrast to Cisplatin, our novel Cisplatin derivatives exhibited comparable activity against Cisplatin sensitive (A2780) and resistant (A2780cisR) ovarian cancer cells. However, we noticed a difference in the behavior of the two Cisplatin derivatives. While RJY13 exhibited strong anti-tumor activity in all in vitro assays, RJY6 was less potent in experiments that were performed in 2D conditions (anti-proliferation and apoptosis inducing assays) and exhibited strong activity in clonogenicity inhibition. Interestingly, we also observed significant differences in the selectivity profile between RJY6 and RJY13 against the non-cancerous cells, such as the HFF and HEK293A/T cells. In general, RJY6 was more selective compared to RJY13. For example, by calculating the ratio of IC_{50}s exhibited against non-cancerous cells (HFF) to the cancerous cell line (A2780), we observed a ratio of 63, 30 and 117.2 when Cisplatin, RJY13, and RJY6, respectively were used. Moreover, comparable outcome were obtained when we compared the relative toxicity to HEK293A in relation to A2780 cells. This argues for an expected better toxicity profile of RJY6, while an enhanced toxicity of RJY13, in comparison to Cisplatin, when using in vivo systems. The mechanisms underlying the differences in behavior of the two compounds are not known and examining the in vivo toxicity is required to evaluate the full potential of our platinum (IV) prodrugs. In addition, mechanisms responsible for the reduced activity of RJY6 in 2D conditions in comparison to assays performed in 3D condition are yet to be determined. However, we hypothesized that differences might relate to varying exposure time in the two types of experiments. While 3D experiments required longer exposure time compared to 2D assays (2 weeks compared to 1–3 days) and therefore the difference in activity might be due to in-efficient bio-conversion of RJY6 compared to RJY13, a hypothesis awaiting experimental validation.

To shed a light on the mechanism responsible for increased potency of RJY6 and RJY13 in comparison to Cisplatin, we evaluated the role of copper transporter, Ctr1, in the uptake of Cisplatin in comparison to the two active Cisplatin (IV) prodrugs. Initially, we noticed that the Cisplatin resistant cells (A2780cisR) expressed very minimal amount of Ctr1 protein in comparison to sensitive cell lines (A2780), arguing for a potential role of Ctr1 in the acquired Cisplatin resistance observed in A2780cisR cells (Fig. 4). Next, we utilized shRNA approach to silence the Ctr1 gene in the sensitive A2780 cell line. We observed that uptake of Cisplatin was high in A2780 Ctr1\(^+\) cells, reduced by 70 % in resistant A2780cisR and by 30 % in A2780 Ctr1\(^-\) (clone #348) cells (Fig. 4c), arguing that Ctr1 protein is partially required for efficient Cisplatin uptake and other transporters besides Ctr1 required for efficient influx of platinum compounds such as Ctr2 [24] and Organic Cation Transporters (Oct 1, 2, 3 and Oct 6) [25, 26]. Interestingly, uptake of RJY6 was marginally reduced upon Ctr1 silencing by 25 %; arguing that uptake of RJY6 might be partially dependent on the Ctr1 transporter. In contrast, uptake of RJY13 was not affected by the reduced Ctr1 expression. In fact, uptake of RJY13 was slightly higher in Ctr1 silenced cells. Our current data are in agreement with previous data reported by Ishida et al., 2002 and Pabla et al., 2009 demonstrating that knockdown of Ctr1 reduced Cisplatin uptake.
Fig. 4 Silencing of Ctr1 and uptake of platinum compounds. 

a Expression of Ctr1 protein was monitored in A2780 and A2780cisR cells. 

b Silencing of Ctr1 gene in A2780 with percentage of decrease in Ctr1 protein levels. 

c Cisplatin uptake into A2780, A2780cisR and A2780 Ctr1− (#348) cells. 

d Uptake of Cisplatin (IV) derivatives (RJY6 and RJY13) into A2780, A2780cisR and A2780 Ctr1− (#348) cells. P values; 

* P < 0.05 and **P < 0.005
into yeast and mammalian cells and blocked Cisplatin-induced cell death [23, 27]. Moreover, Holzer et al. 2004 reported that Ctr1 controls the cellular accumulation of Cisplatin, Carboplatin, and Oxaliplatin at low concentrations, however, accumulation of Oxaliplatin is not dependent on Ctr1 at higher concentrations [22]. Our working hypothesis argues that uptake of RJY6 and RJY13 are largely Ctr1-independent and probably more efficient than that of Cisplatin and hence the enhanced activity. Moreover, similarly to other reported platinum (IV) prodrugs, enhanced activity and ability to overcome chemo resistance might be related to the lipophilicity of the prodrugs that favors its cellular accumulation by passive diffusion [28]. We expected that our platinum (IV) prodrugs will exhibit similar cellular activity as platinum (II). However, this assumption needed to be experimentally validated. In some cases, Cisplatin prodrugs such as Oxoplatin exhibit different intracellular effects mediated by differences in induction of stress responses [29]. Nevertheless, our data illustrated the therapeutic potential of platinum (IV) prodrugs in overcoming Cisplatin chemo resistance in cancer cells and potential better in vivo cytotoxic profile for some of them.

**Conclusion**

In this report we explored the therapeutic potential of our platinum (IV) prodrugs in inducing anti-cancer activity to Cisplatin resistant and sensitive ovarian cancer cell lines and showed that the uptake of Cisplatin is partially dependent on Ctr1 transporter, while uptake of our platinum (IV) prodrugs is largely Ctr1-independent. Moreover, our results demonstrated the potential of platinum (IV) prodrugs in overcoming acquired and inherited drug resistance in cancer cell lines and their therapeutic potential in cancer therapy.

**Abbreviations**

2D: two dimensional; 3D: three dimensional; A2780/cis: cisplatin sensitive ovarian cancer cell line; A2780/or: cisplatin resistant ovarian cancer cell line; Ads: human species C adenovirus serotype 5; AKT: protein kinase B; CDDP: cis-Diaminedichloroplatinum (II) [(en-Pc)(H2)]2; CML: chronic myelogenous leukemia; Ctr1: copper transporter-1; CV: coefficient of variation; DMEM: Dulbecco’s Modified Eagle’s Medium; DMSO: dimethyl sulfoxide; ELISA: enzyme-linked immunosorbent assay; ESIMS: electrospray ionization mass spectrometry; FBS: fetal bovine serum; FT-IR: fourier transform infrared spectroscopy; HEK293: human embryonic kidney cell; HFF: human foreskin fibroblast; HT29: colon cancer cell line; ICP-MS: inductively coupled plasma mass spectrometry; mTOR: mammalian target of rapamycin; MTT: 3-(4,5-dimethyltetrazolium-2)-5-diphenyltetrakissulfonate bromide; NMR: proton nuclear magnetic resonance; PMSF: phenylmethylsulfonyl fluoride; PBS: phosphate-buffered saline; PMSF: phenylmethylsulfonyl fluoride; RPMI: Roswell Park Memorial Institute; SDS: sodium dodecyl sulfate; SV40: simian vacuolating virus 40; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulphenyI)-2H-tetrazolium-5-carboxanilide.

**Competing interests**

The authors declare that they have no competing interests.

**Author contributions**

ER carried out the experiments aimed to evaluate the anti-cancer activity (anti-proliferation and apoptosis induction experiments) of RJY compounds. HK performed the Ctrl1 silencing and the clonogenicity inhibition experiments. RS synthesized the various platinium IV prodrugs. YN supervise the platinum IV prodrug synthesis and performed the statistical analysis. MR participated in the design of the study and edited the manuscript. JM conceived the study, supervised it and wrote the manuscript. All authors read and approved the final manuscript.

**Acknowledgments**

This work was supported in part by DFG-RU 728/3-2 to MR, YN and JM.

**Author details**

1. Cancer Drug Discovery Program, Migal, Galilee Research Institute, P.O. Box 831, Kiryat Shmona 11016, Israel. 2. Anticancer Drugs Research Lab, Faculty of Pharmacy, Al-Quds University, P.O. Box 20002, Jerusalem, Abu-Dies, Palestinian Authority. 3. Medizinische Klinik II/Abt. Hämatologie, Klinikum der Johann Wolfgang Goethe Universität, Theodor-Stern Kai 7, 60590 Frankfurt, Germany. 4. The Department of Nutritional Sciences, Tel Hai College, Kiryat Shmona, Israel.

**Received:** 28 July 2015 **Accepted:** 16 February 2016 **Published online:** 23 February 2016

**References**

1. Rosenberg B, VanCamp L, Kiraps T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–9.
2. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93–130.
3. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 1990;23:35–43.
4. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol. 1999;11:68–75.
5. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1998;241:1813–5.
6. Peng DJ, Wang J, Zhou JY, Wu GS. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun. 2010;394:600–5.
7. Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1995;15:191–219.
8. Raymond E, Fahvis S, Wosyanski JW, Chaney SG. Oxoplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25:4–12.
9. Storald B, Pavelis N, Davey R. Oxaplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev. 2007;33:347–57.
10. Storald B, Davey M. Understanding cisplatin resistance using cellular models. JUBMB Life. 2007;5:969–9.
11. Doshi G, Sonpavde G, Sternberg CN. Clinical and pharmacokinetic evaluation of satraplatin. Expert Opin Drug Metab Toxicol. 2012;8:103–11.
12. Bhargava A, Vaishampayan UN. Satraplatin: leading the new generation of oral platinum agents. Expert Opin Invest Drugs. 2009;18:787–97.
13. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res. 2008;14:1633–8.
14. Brandon RJ, Dabrowowicz JC. Synthesis, characterization, and properties of a group of platinum (IV) complexes. J Med Chem. 1984;27:861–5.
15. Car JL, Tingle MD, McKeage MJ. Satraplatin activation by haemoglobin, cytchrome C and liver microsomes in vitro. Cancer Chemother Pharmacol. 2006;57:983–90.
16. Gibbons GR, Wyrick S, Chaney SG. Rapid reduction of tetrachloro(D,L-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res. 1989;49:1402–7.
17. Ruini N, Rvasdheh H, Wasser S, Konkimalla B, Effert T, et al. Daedalea gibbosa substances inhibit UPS-induced expression of iNOS by suppression of NF-kappaB and MAPK activities in RAW 264.7 macrophage cells. Int J Mol Med. 2010;25:421–32.
18. Hannun YA, Obeid LM. Mechanisms of ceramide-mediated apoptosis. Adv Exp Med Biol. 1997;407:145–9.
19. Dotan N, Wasser SP, Mahajna J. Inhibition of the androgen receptor activity by Coprinus comatus substances. Nutr Cancer. 2011;63:1316–27.
20. Gabano E, Colangelo D, Gezzi AR, Osella D. The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs. J Inorg Biochem. 2008;102:269–35.
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
22. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004;66:817–23.

23. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol. 2009;296:F505–11.

24. Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 2009;15:4312–21.

25. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011;14:22–34.

26. Kunii E, Oguri T, Kasai D, Ozasa H, Uemura T, et al. Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol. 2015;75:985–91.

27. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002;99:14298–302.

28. Gandin V, Marzano C, Pelosi G, Ravera M, Gabano E, Osella D. trans, cis, cis-bis(benzoato)dichlorido(cyclohexane-1R,2R-diamine)platinum(IV): a prodrug candidate for the treatment of oxaliplatin-refractory colorectal cancer. ChemMedChem. 2014;9:1299–305.

29. Hamilton G. Comparison of intracellular stress response of NCI-H526 Small Cell Lung Cancer (SCLC) cells to platinum(II) Cisplatin and platinum(IV) oxoplatin. Cancers (Basel). 2014;6:1487–99.